These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
106 related articles for article (PubMed ID: 12400987)
21. Interleukin-2 in outpatients with renal cell carcinoma: SCAPP1 trial. Tourani JM; Grise P; Lucas V; Mayeur D; Dufour B; Di Palma M; Boaziz C; Pavlovitch JM; Pujade-Lauraine E; Larregain D; Untereiner M Cancer Biother Radiopharm; 1996 Oct; 11(5):297-300. PubMed ID: 10851507 [No Abstract] [Full Text] [Related]
22. Update on the application of interleukin-2 in the treatment of renal cell carcinoma. McDermott DF Clin Cancer Res; 2007 Jan; 13(2 Pt 2):716s-720s. PubMed ID: 17255299 [TBL] [Abstract][Full Text] [Related]
23. Recurrence of pemphigus vulgaris associated with interleukin 2 therapy. Prussick R; Plott RT; Stanley JR Arch Dermatol; 1994 Jul; 130(7):890-3. PubMed ID: 7794299 [TBL] [Abstract][Full Text] [Related]
24. Complete response in a cutaneous facial metastatic nodule from renal cell carcinoma after hypofractionated radiotherapy. Gay HA; Cavalieri R; Allison RR; Finley J; Quan WD Dermatol Online J; 2007 Oct; 13(4):6. PubMed ID: 18319003 [TBL] [Abstract][Full Text] [Related]
25. Systemic chemotherapy and chemoimmunotherapy for metastatic renal cell cancer. Heinzer H; Huland E; Huland H World J Urol; 2001 Apr; 19(2):111-9. PubMed ID: 11374313 [TBL] [Abstract][Full Text] [Related]
29. [Advice from Public Health Council concerning administration of interleukin-2 in patients with renal cell tumor]. van Maanen L Oncologica; 1994 May; 11(2):31-2. PubMed ID: 8025832 [No Abstract] [Full Text] [Related]
30. Prognostic implications of polymorphisms and interleukin-2 therapy for renal cell carcinoma. Gardner TA; Logan T J Urol; 2009 Aug; 182(2):425-6. PubMed ID: 19524946 [No Abstract] [Full Text] [Related]
31. Immunotherapy in metastatic renal cell carcinoma. Rohrmann K; Staehler M; Haseke N; Bachmann A; Stief CG; Siebels M World J Urol; 2005 Jul; 23(3):196-201. PubMed ID: 15806434 [TBL] [Abstract][Full Text] [Related]
32. Interleukin-2 chronotherapy for metastatic renal cell carcinoma: Results of a phase I-II study. Re GL; Santeufemia DA; Re FL; Bortolus R; Doretto P; Marus W; Buttazzi L; Lenardon O; Falda A; Piazza R; Sulfaro S Cytokine; 2020 Apr; 128():154984. PubMed ID: 31972343 [TBL] [Abstract][Full Text] [Related]
33. Interleukin-2 continuous infusion and angiogenesis surrogate markers in metastatic renal cell carcinoma. Simonelli C; Talamini R; Bearz A; Berretta M; Spazzapan S; Monini P; Sgadari C; Sartor I; Ensoli B; Tirelli U Ann Oncol; 2006 Aug; 17(8):1335-6. PubMed ID: 16569648 [No Abstract] [Full Text] [Related]